Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126432731 | 12643273 | 1 | I | 20160808 | 20160811 | 20160811 | EXP | CN-ROCHE-1810583 | ROCHE | LI H, SHAO B, YAN Y, SONG G, LIU X, WANG J AND LIANG X. EFFICACY AND SAFETY OF TRASTUZUMAB COMBINED WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT AND BEYOND PROGRESSION OF HER2-OVEREXPRESSING ADVANCED BREAST CANCER. CHINESE JOURNAL OF CANCER RESEARCH = CHUNG-KUO YEN CHENG YEN CHIU 2016 JUN;28 (3):330-338. | 0.00 | F | Y | 0.00000 | 20160811 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126432731 | 12643273 | 1 | PS | Trastuzumab | TRASTUZUMAB | 1 | Intravenous (not otherwise specified) | 103792 | SOLUTION FOR INFUSION | ||||||||||
| 126432731 | 12643273 | 2 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | DAY 1 AND DAY 14 | U | 20896 | 1000 | MG/M**2 | TABLET | BID | |||||
| 126432731 | 12643273 | 3 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | DAY 1 OR SAME DOSE DIVIDED IN DAY 1 AND THE EIGHTH DAY | U | 0 | 175 | MG/M**2 | Q3W | ||||||
| 126432731 | 12643273 | 4 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | U | 0 | ||||||||||
| 126432731 | 12643273 | 5 | SS | VINORELBINE | VINORELBINEVINORELBINE TARTRATE | 1 | Unknown | DAY 1 AND DAY 8 | U | 0 | 30 | MG/M**2 | Q3W | ||||||
| 126432731 | 12643273 | 6 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | DAY 1 AND DAY 8 | U | 0 | 1000 | MG/M**2 | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126432731 | 12643273 | 1 | HER-2 positive breast cancer |
| 126432731 | 12643273 | 2 | HER-2 positive breast cancer |
| 126432731 | 12643273 | 3 | HER-2 positive breast cancer |
| 126432731 | 12643273 | 4 | HER-2 positive breast cancer |
| 126432731 | 12643273 | 5 | HER-2 positive breast cancer |
| 126432731 | 12643273 | 6 | HER-2 positive breast cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126432731 | 12643273 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126432731 | 12643273 | Angina pectoris | |
| 126432731 | 12643273 | Blood creatinine increased | |
| 126432731 | 12643273 | Chills | |
| 126432731 | 12643273 | Extremity necrosis | |
| 126432731 | 12643273 | Haematotoxicity | |
| 126432731 | 12643273 | Hepatic failure | |
| 126432731 | 12643273 | Metastases to central nervous system | |
| 126432731 | 12643273 | Pyrexia | |
| 126432731 | 12643273 | Thrombosis | |
| 126432731 | 12643273 | Traumatic lung injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |